Previously approved drugs that target autophagy, may also reduce the risk of thrombosis in APS patients by directly modulating the binding of aPLs/β2GPI complexes to phospholipids in monocytes40. The gene discussed is APOH; the disease is autoimmune polyendocrinopathy.